Ramdev’s Patanjali Ayurved claims it can "cure COVID-19 in 7 days"

June 23, 2020 04:43 pm | Updated 04:43 pm IST - Haridwar/New Delhi

Yoga guru Ramdev’s Patanjali Ayurved on Tuesday launched what he claimed was the first ayurvedic medicine to cure COVID-19 even as the scientific community is struggling to develop an effective cure for the highly contagious disease.

Patanjali claimed ‘Coronil’ and ‘Swasari’ had shown “100% favourable results” during clinical trials on affected patients, at Patanjali Yogpeeth in Haridwar.

Launching the medicines at a press conference in Haridwar, Ramdev claimed “100 per cent recovery from COVID-19 within seven days of consuming the medicine is guaranteed.” This is not an immunity booster but a coronavirus cure, he added.

Manufactured by Haridwar-based Divya Pharmacy and Patanjali Ayurved Ltd, the medicine is the result of a research partnership between Patanjali Research Institute and the Jaipur-based National Institute of Medical Sciences.

The drug was clinically tried on 280 COVID-19 positive persons out of which 69% were cured within three days, Ramdev said at the launch of the medicine held at Patanjali Yogpeeth in the presence of NIMS Director Dr Balbir Singh Tomar and allopathic and ayurvedic experts involved in the research behind making the drug.

The Corona kit consists of three medicines - Coronil, Swasari and Anu Tel. Coronil is made of the extracts of pure Giloy, Tulsi and Ashwagandha. Shwasari works on strengthening the respiratory system and cures the obvious symptoms of corona including cough, cold and fever, while Anu Tel is a nasal drop that helps build immunity, the firm said.

The kit is priced at ₹545 for 30 days, can be ordered online through a mobile app from next Monday.

Patanjali claims that its corona medicine kit can also be taken as prevention for coronavirus.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.